Michael A. Linden, MD, PhD Profile
Michael A. Linden, MD, PhD

@mnhemepath

Followers
1K
Following
190
Statuses
257

I am a hematopathologist at the University of Minnesota. I love using flow cytometry to augment what I see under my scope! #hemepath #flowcytometry

Saint Paul, MN
Joined February 2020
Don't wanna be here? Send us removal request.
@mnhemepath
Michael A. Linden, MD, PhD
10 months
17 people, including former fellows as well as current and former faculty members, donated to @TheUSCAP in honor of Dr. Robert McKenna's mentorship over the years. Today we adorned his badge with 17 mentor ribbons in honor of this tribute. ๐Ÿ™‚#mmsm #PathTwitter #PathX #leusm
Tweet media one
4
5
48
@mnhemepath
Michael A. Linden, MD, PhD
5 days
This is a great discussion forum for those in #flowcytometry labs #flowedu #pathX
@ICCS_Education
ICCS_Education
5 days
ICCS has launched an all-new forum for members! The first channel discusses the new LDT regulations. Additional channels will be launched in the future. Go to the ICCS website and log in to access the forum: Interested in ICCS membership? It's a great value, and details are available at this link:
Tweet media one
0
4
9
@mnhemepath
Michael A. Linden, MD, PhD
7 days
In addition to a a match for our #hemepath fellowship, I'm pleased to announce additional leadership - kudos to @TashakoriM on her recent appointment as associate fellowship program director. #leusm #lymsm #mmsm #pathX #FlowEdu @chevomd20 @UMNLabMedPath
Tweet media one
1
1
25
@mnhemepath
Michael A. Linden, MD, PhD
1 month
Our #flowcytometry lab is looking for a new supervisor - if you are looking to lead a great lab consider applying by clicking on the link below. #hemepath #flowedu
0
5
3
@mnhemepath
Michael A. Linden, MD, PhD
2 months
Another innovatitve @ALLIANCE_org trial that I'm involved in - led by @DrMHB1 and @YEfebera - proud to be involved in the biobanking and correlative studies, some of which will be performed here at Minnesota. #mmsm #flowcytometry #flowedu
@ALLIANCE_org
Alliance for Clinical Trials in Oncology
2 months
#DYK @DrMHB1@DanaFarber @YEfebera @OhioHealth co-lead @ALLIANCE_org A062101 to test the combination of 2 approved drugs & an experimental drug in pts w/relapsed or refractory #multiplemyeloma. Learn more: #NCI #NCTN @theMMRF @IMFMyeloma @MMSMChats @MM_Hub
Tweet media one
0
1
4
@mnhemepath
Michael A. Linden, MD, PhD
2 months
Check out @stuchman1's new trial in myeloma - proud to be involved in the biobanking and correlative studies for this study, with some of the biomarkers to be tested here at Minnesota #mmsm #flowcytometry #flowedu
@ALLIANCE_org
Alliance for Clinical Trials in Oncology
2 months
#ICYMI - .@stuchman1 @UNC_Lineberger leads @ALLIANCE_org A062102-a trial that compares iberdomide maintenance therapy to disease monitoring to improve survival in pts who have received idecabtagene vicleucel for multiple #myeloma: #mmsm @MM_Hub #NCI #NCTN
Tweet media one
0
0
2
@mnhemepath
Michael A. Linden, MD, PhD
2 months
Seeing the myeloma field advance to this point is amazing! There is a bright future ahead for our patients. #mmsm
@Rfonsi1
Rafael Fonseca MD ๐Ÿฆ”๐Ÿ‡บ๐Ÿ‡ธ๐Ÿœ๐Ÿ‡ฒ๐Ÿ‡ฝ
2 months
Eight years out from SCT. Sustained MRD-. Merry Xmas! #mmsm
Tweet media one
1
1
11
@mnhemepath
Michael A. Linden, MD, PhD
2 months
Yes - at #USCAP2025 we have looked at how #p53 influences #flowcytometry immunophenotype - will be a great poster!!! #flowedu #PathMatch2025
@TashakoriM
Mehrnoosh Tashakori, MD PhD
2 months
Lucky to work with such an incredible team!! Stay tuned for more p53-related studies on myeloid neoplasms from our group at #USCAP2025 ๐Ÿ˜Š #hemepath #leusm #p53 @UMNLabMedPath @umnmedschool
0
2
9
@mnhemepath
Michael A. Linden, MD, PhD
2 months
So proud of @TashakoriM's work on this study! #hemepath #leusm #PathTwitter #PathX The prognostic effect of blast count in TP53 mutant myeloid neoplasms โ€“the Minnesota experience
1
2
7
@mnhemepath
Michael A. Linden, MD, PhD
2 months
Did you know that our #hemepath faculty trained at 7 different programs? It makes it a fun place to work and train! See news article below... @ismailelbaz88 @CadePathologyMD @SamreenfatimaMD @TashakoriM @AmyBeckman272 @chevomd20
Tweet media one
0
3
16
@mnhemepath
Michael A. Linden, MD, PhD
2 months
0
0
1
@mnhemepath
Michael A. Linden, MD, PhD
2 months
0
0
1
@mnhemepath
Michael A. Linden, MD, PhD
2 months
@AmeetRKini @SamreenfatimaMD We are too! So amazing to have her as a colleague and see @SamreenfatimaMD each day!
1
0
4
@mnhemepath
Michael A. Linden, MD, PhD
2 months
If I can copy @KMirza's gif - we are all so proud of @SamreenfatimaMD upon completion of this important milestone! #hemepath boards - knocked out of the park! Congratulations!
@KMirza
Kamran Mirza MD PhD - ฺฉุงู…ุฑุงู† ู…ุฑุฒุง
2 months
1
1
21
@mnhemepath
Michael A. Linden, MD, PhD
2 months
0
0
2
@mnhemepath
Michael A. Linden, MD, PhD
3 months
1
0
4
@mnhemepath
Michael A. Linden, MD, PhD
4 months
Flow cytometry peeps - we need more medical directors and technologists on board to volunteer to work with ICCS to help guide us on how the Final Rule will guide LDT testing. Iโ€™m a member of the Advocacy committee and itโ€™s a great group. See form below. #FlowICCS24
@ICCS_Education
ICCS_Education
4 months
The FDA's Final Rule for the regulation of Laboratory Developed Tests (LDTs) is here, and is likely to have a major impact on flow cytometry testing in the US. To help understand and plan for these changes, consider joining the ICCS LDT working group by contacting Sara Monaghan: #FlowICCS24
Tweet media one
0
3
7
@mnhemepath
Michael A. Linden, MD, PhD
4 months
Useful info to remember - the immunophenotype of normal PDCs #FlowICCS24
@AmeetRKini
Ameet Kini, MD, PhD
4 months
The immunophenotype of normal plasmacytoid dendritic cells, presented by Wei Wang during his CSI case at #FlowICCS24 #FlowEdu #hemepath
Tweet media one
0
6
13